Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
ZYME.OQ - Zymeworks Inc
Zymeworks Inc at TD Cowen Healthcare Conference
Mar 02, 2026 / 07:30PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Joining us for the forty-sixth annual TDC Healthcare Conference, I'm Yon Werber, biotech analyst here at TDC. It's a great pleasure to have with us today, Adam Sawitz, who's the Chief Development Officer at Zy and, also, a partner at, EO One.
Adam is now in charge of, all clinical development and very much, involved in strategy as well as Zy continues to develop their own products. This is a name that we've been very excited about both because of Zahara. And the internally pipeline, including folate receptor alpha ADC, which looks, very differentiated from Mirena S, now in a phase one dose escalation. Also the GPC3 ADC, which is, really promising, especially on the heels of B1, mentioning that their GPC 3, 41BB, had really nice
Trustpilot
